You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, February 2013
|
| DOI | 10.1186/bcr3384 |
| Pubmed ID | |
| Authors |
Carsten Denkert, Jens Huober, Sibylle Loibl, Judith Prinzler, Ralf Kronenwett, Silvia Darb-Esfahani, Jan C Brase, Christine Solbach, Keyur Mehta, Peter A Fasching, Bruno V Sinn, Knut Engels, Mattea Reinisch, Martin-Leo Hansmann, Hans Tesch, Gunter von Minckwitz, Michael Untch |
| Abstract |
Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas from patients treated within the neoadjuvant GeparQuattro trial. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 50% |
| United States | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 3% |
| Norway | 1 | 1% |
| Portugal | 1 | 1% |
| Denmark | 1 | 1% |
| Japan | 1 | 1% |
| Unknown | 63 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 32% |
| Student > Ph. D. Student | 8 | 12% |
| Other | 5 | 7% |
| Student > Master | 5 | 7% |
| Student > Bachelor | 3 | 4% |
| Other | 9 | 13% |
| Unknown | 17 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 32% |
| Agricultural and Biological Sciences | 12 | 17% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Other | 2 | 3% |
| Unknown | 17 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2014.
All research outputs
#17,236,404
of 25,374,647 outputs
Outputs from Breast Cancer Research
#1,530
of 2,053 outputs
Outputs of similar age
#193,106
of 291,036 outputs
Outputs of similar age from Breast Cancer Research
#20
of 27 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,036 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.